Coverage policy updates

Policy changes Backwork has recorded, newest first. The most recent change on record is from October 24, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.

Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.

Recorded changes

86,510 on record

Recorded policy changes, newest first
Recorded	Payer	Policy	Change
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	PET or PET/CT for Anal CarcinomaPayerPolicy · ARKBLUE-PET-OR-PET-CT-FOR-ANAL-CARCINOMA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	PET or PET/CT, for Alzheimer's Disease, Dementia, or Cognitive ImpairmentPayerPolicy · ARKBLUE-PET-OR-PET-CT-FOR-ALZHEIMER-S-DISEASE-DEMENTIA-OR-COGNITIVE-IMPAIRMENT	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	PET or PET/CT for Oncologic Applications for ASE/PSE ContractsPayerPolicy · ARKBLUE-PET-OR-PET-CT-FOR-ONCOLOGIC-APPLICATIONS-FOR-ASE-PSE-CONTRACTS	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Pertuzumab, trastuzumab and hyaluronidase-zzxf (e.g., PHESGO)PayerPolicy · ARKBLUE-PERTUZUMAB-TRASTUZUMAB-AND-HYALURONIDASE-ZZXF-E-G-PHESGO	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Pertuzumab (e.g., Perjeta)PayerPolicy · ARKBLUE-PERTUZUMAB-E-G-PERJETA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Peroral Endoscopic Myotomy (POEM)PayerPolicy · ARKBLUE-PERORAL-ENDOSCOPIC-MYOTOMY-POEM	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Periureteral Bulking Agents as a Treatment of Vesicoureteral Reflux (VUR)PayerPolicy · ARKBLUE-PERIURETERAL-BULKING-AGENTS-AS-A-TREATMENT-OF-VESICOURETERAL-REFLUX-VUR	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Peripheral Nerve StimulationPayerPolicy · ARKBLUE-PERIPHERAL-NERVE-STIMULATION	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Percutaneous Transluminal Endovascular Graft for Abdominal Aortic AneurysmPayerPolicy · ARKBLUE-PERCUTANEOUS-TRANSLUMINAL-ENDOVASCULAR-GRAFT-FOR-ABDOMINAL-AORTIC-ANEURYSM	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Percutaneous Revascularization Procedures for Lower Extremity, Abdominal Aortic & Visceral ArteriesPayerPolicy · ARKBLUE-PERCUTANEOUS-REVASCULARIZATION-PROCEDURES-FOR-LOWER-EXTREMITY-ABDOMINAL-AORTIC-VISCERAL-ARTERIES	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Tibial Nerve StimulationPayerPolicy · ARKBLUE-TIBIAL-NERVE-STIMULATION	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Pemetrexed (e.g., Alimta)PayerPolicy · ARKBLUE-PEMETREXED-E-G-ALIMTA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Pembrolizumab and Berahyaluronidase alfa-pmph (e.g., Keytruda Qlex)PayerPolicy · ARKBLUE-PEMBROLIZUMAB-AND-BERAHYALURONIDASE-ALFA-PMPH-E-G-KEYTRUDA-QLEX	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Pembrolizumab (e.g., Keytruda)PayerPolicy · ARKBLUE-PEMBROLIZUMAB-E-G-KEYTRUDA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Pegloticase (e.g., Krystexxa)PayerPolicy · ARKBLUE-PEGLOTICASE-E-G-KRYSTEXXA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Pegcetacoplan Intravitreal (e.g., Syfovre)PayerPolicy · ARKBLUE-PEGCETACOPLAN-INTRAVITREAL-E-G-SYFOVRE	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Pegcetacoplan (e.g., Empaveli)PayerPolicy · ARKBLUE-PEGCETACOPLAN-E-G-EMPAVELI	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Patient-Actuated Mechanical Devices (Range of Motion & Stretching Devices)PayerPolicy · ARKBLUE-PATIENT-ACTUATED-MECHANICAL-DEVICES-RANGE-OF-MOTION-STRETCHING-DEVICES	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Pasireotide (e.g., Signifor or Signifor LAR)PayerPolicy · ARKBLUE-PASIREOTIDE-E-G-SIGNIFOR-OR-SIGNIFOR-LAR	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Panitumumab (e.g., Vectibix)PayerPolicy · ARKBLUE-PANITUMUMAB-E-G-VECTIBIX	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Paliperidone Palmitate (e.g., Long-acting Injectables Invega Sustenna & Invega Trinza, Erzofri)PayerPolicy · ARKBLUE-PALIPERIDONE-PALMITATE-E-G-LONG-ACTING-INJECTABL-319D8B4C9E	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Pain Management, Facet Joint BlockPayerPolicy · ARKBLUE-PAIN-MANAGEMENT-FACET-JOINT-BLOCK	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Ovarian and Internal Iliac Vein Embolization as a Treatment of Pelvic Congestion SyndromePayerPolicy · ARKBLUE-OVARIAN-AND-INTERNAL-ILIAC-VEIN-EMBOLIZATION-AS-A-TREATMENT-OF-PELVIC-CONGESTION-SYNDROME	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Osteochondral Allograft and/or Mosaicplasty for Osteochondral Defects of the KneePayerPolicy · ARKBLUE-OSTEOCHONDRAL-ALLOGRAFT-AND-OR-MOSAICPLASTY-FOR-OSTEOCHONDRAL-DEFECTS-OF-THE-KNEE	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Orthoptic Training for the Treatment of Vision and Learning DisabilitiesPayerPolicy · ARKBLUE-ORTHOPTIC-TRAINING-FOR-THE-TREATMENT-OF-VISION-AND-LEARNING-DISABILITIES	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Orthopedic Postoperative Rehabilitative Devices in the Home Setting (eg. CPM; ROMTech)PayerPolicy · ARKBLUE-ORTHOPEDIC-POSTOPERATIVE-REHABILITATIVE-DEVICES-IN-THE-HOME-SETTING-EG-CPM-ROMTECH	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Orthopedic ImplantsPayerPolicy · ARKBLUE-ORTHOPEDIC-IMPLANTS	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Optical Diagnostic Devices for Evaluating Skin Lesions Suspected of MalignancyPayerPolicy · ARKBLUE-OPTICAL-DIAGNOSTIC-DEVICES-FOR-EVALUATING-SKIN-LESIONS-SUSPECTED-OF-MALIGNANCY	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Optical Coherence Tomography Anterior Eye Segment ImagingPayerPolicy · ARKBLUE-OPTICAL-COHERENCE-TOMOGRAPHY-ANTERIOR-EYE-SEGMENT-IMAGING	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Ophthalmologic Techniques That Evaluate the Posterior Segment for GlaucomaPayerPolicy · ARKBLUE-OPHTHALMOLOGIC-TECHNIQUES-THAT-EVALUATE-THE-POSTERIOR-SEGMENT-FOR-GLAUCOMA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Oophorectomy, ProphylacticPayerPolicy · ARKBLUE-OOPHORECTOMY-PROPHYLACTIC	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Onasemnogene abeparvovec-xioi (e.g., Zolgensma)PayerPolicy · ARKBLUE-ONASEMNOGENE-ABEPARVOVEC-XIOI-E-G-ZOLGENSMA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Omidubicel (e.g., Omisirge) as Adjunct Treatment for Hematologic MalignanciesPayerPolicy · ARKBLUE-OMIDUBICEL-E-G-OMISIRGE-AS-ADJUNCT-TREATMENT-FOR-HEMATOLOGIC-MALIGNANCIES	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Olipudase alfa (e.g., Xenpozyme)PayerPolicy · ARKBLUE-OLIPUDASE-ALFA-E-G-XENPOZYME	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Octreotide Acetate (e.g., Sandostatin) for Injectable Suspension (e.g., Sandostatin LAR Depot)PayerPolicy · ARKBLUE-OCTREOTIDE-ACETATE-E-G-SANDOSTATIN-FOR-INJECTABLE-SUSPENSION-E-G-SANDOSTATIN-LAR-DEPOT	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Ocrelizumab (e.g., Ocrevus) and Ocrelizumab with Hyaluronidase (e.g., Ocrevus Zunovo)PayerPolicy · ARKBLUE-OCRELIZUMAB-E-G-OCREVUS-AND-OCRELIZUMAB-WITH-HYALURONIDASE-E-G-OCREVUS-ZUNOVO	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Obinutuzumab (e.g., Gazyva)PayerPolicy · ARKBLUE-OBINUTUZUMAB-E-G-GAZYVA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Obecabtagene autoleucel (e.g., Aucatzyl)PayerPolicy · ARKBLUE-OBECABTAGENE-AUTOLEUCEL-E-G-AUCATZYL	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Osteochondral Autograft Transfer (OATS) and/or Mosaicplasty For Osteochondral Defects of the KneePayerPolicy · ARKBLUE-OSTEOCHONDRAL-AUTOGRAFT-TRANSFER-OATS-AND-OR-MOSAICPLASTY-FOR-OSTEOCHONDRAL-DEFECTS-OF-THE-KNEE	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Nutritional SupplementsPayerPolicy · ARKBLUE-NUTRITIONAL-SUPPLEMENTS	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Nutritional Panel Testing (NutrEval, ONE FMV)PayerPolicy · ARKBLUE-NUTRITIONAL-PANEL-TESTING-NUTREVAL-ONE-FMVTM	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Nusinersen (e.g., Spinraza)PayerPolicy · ARKBLUE-NUSINERSEN-E-G-SPINRAZA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Noninvasive Imaging Technologies for Evaluation of Hepatic Fibrosis and Other Tissues (Elastography)PayerPolicy · ARKBLUE-NONINVASIVE-IMAGING-TECHNOLOGIES-FOR-EVALUATION-OF-HEPATIC-FIBROSIS-AND-OTHER-TISSUES-ELASTOGRAPHY	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Non-Myeloablative Allogeneic Stem Cell TransplantationPayerPolicy · ARKBLUE-NON-MYELOABLATIVE-ALLOGENEIC-STEM-CELL-TRANSPLANTATION	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Non-Invasive Positive Airway Pressure for Chronic Obstructive Pulmonary Disease, Chronic Respiratory Failure, Thoracic Restrictive Disorders, and Hypoventilation SyndromesPayerPolicy · ARKBLUE-NON-INVASIVE-POSITIVE-AIRWAY-PRESSURE-FOR-CHRONIC-OBSTRUCTIVE-PULMONARY-DISEASE-CHRONIC-RESPIRATORY-FAILURE-THORACIC-RESTRICTIVE-DISORDERS-AND-HYPOVENTILATION-S	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Non-Bevacizumab Vascular Epithelial Growth Factors for Ophthalmic Use (e.g., Beovu, Byooviz, Cimerli, Eylea, Eylea HD, Lucentis, Pavblu, Vabysmo, Enzeevu, Ahzantive, Yesafili, Opuviz)PayerPolicy · ARKBLUE-NON-BEVACIZUMAB-VASCULAR-EPITHELIAL-GROWTH-FACTORS-FOR-OPHTHALMIC-USE-E-G-BEOVU-BYOOVIZ-CIMERLI-EYLEA-EYLEA-HD-LUCENTIS-PAVBLU-VABYSMO-ENZEEVU-AHZANTIVE-YESAFIL	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Nogapendekin alfa inbakicept-pmln (e.g., Anktiva)PayerPolicy · ARKBLUE-NOGAPENDEKIN-ALFA-INBAKICEPT-PMLN-E-G-ANKTIVA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Nivolumab and relatlimab-rmbw (e.g., Opdualag)PayerPolicy · ARKBLUE-NIVOLUMAB-AND-RELATLIMAB-RMBW-E-G-OPDUALAG	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Nivolumab and Hyaluronidase (e.g., Opdivo Qvantig)PayerPolicy · ARKBLUE-NIVOLUMAB-AND-HYALURONIDASE-E-G-OPDIVO-QVANTIG	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Nivolumab (e.g., Opdivo)PayerPolicy · ARKBLUE-NIVOLUMAB-E-G-OPDIVO	New policy